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Abstract
Background: A functional polymorphism located at 21 from the start codon of the CD40 gene, rs1883832, was previously
reported to disrupt a Kozak sequence essential for translation. It has been consistently associated with Graves’ disease risk in
populations of different ethnicity and genetic proxies of this variant evaluated in genome-wide association studies have
shown evidence of an effect in rheumatoid arthritis and multiple sclerosis (MS) susceptibility. However, the protective allele
associated with Graves’ disease or rheumatoid arthritis has shown a risk role in MS, an effect that we aimed to replicate in
the present work. We hypothesized that this functional polymorphism might also show an association with other complex
autoimmune condition such as inflammatory bowel disease, given the CD40 overexpression previously observed in Crohn’s
disease (CD) lesions.
Methodology: Genotyping of rs1883832C.T was performed in 1564 MS, 1102 CD and 969 ulcerative colitis (UC) Spanish
patients and in 2948 ethnically matched controls by TaqMan chemistry.
Principal Findings: The observed effect of the minor allele rs1883832T was replicated in our independent Spanish MS
cohort [p= 0.025; OR (95% CI)= 1.12 (1.01–1.23)]. The frequency of the minor allele was also significantly higher in CD
patients than in controls [p= 0.002; OR (95% CI)= 1.19 (1.06–1.33)]. This increased predisposition was not detected in UC
patients [p= 0.5; OR (95% CI)= 1.04 (0.93–1.17)].
Conclusion: The impact of CD40 rs1883832 on MS and CD risk points to a common signaling shared by these autoimmune
conditions.
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Introduction
In the past three years genome-wide association studies have
identified literally hundreds of genetic loci involved in the
susceptibility conferred to complex inherited traits. Even though
this scenario represents an extraordinary advance in complex
disease genetics, the modest effect sizes of the common
polymorphisms found associated explain only a small fraction of
the heritability in most of these multifactorial conditions,
suggesting that many more loci remain to be discovered. One of
the genes encoding a member of the tumor necrosis factor receptor
family that plays a key role in adaptive immunity is CD40
(MIM*109535) [1]. T-cell priming and B-cell activation can occur
in the absence of the CD40/CD40-ligand costimulatory signal,
but many immune functions are impaired without this interaction,
underscoring its importance for an adequate immune response.
Candidate gene studies reported the association of a functional
CD40 polymorphism with Graves’ disease; moreover, the
association of this variant was replicated in populations of different
ethnicity including Caucasians, Koreans, and Japanese [2–4]. This
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functional polymorphism, rs1883832, is located at 21 from the
ATG within a Kozak sequence, a stretch of nucleotides essential
for translation that is flanking the start codon in vertebrate genes
[5]. The common allele of rs1883832 increased the translational
efficiency of CD40 transcripts, resulting in 15–32% more CD40
protein than in the presence of the minor allele [6]. CD40 has been
recently associated with rheumatoid arthritis through the meta-
analysis of two genome-wide studies conducted in European
populations [7]. The common allele frequency of a polymorphism
located in the second intron of the CD40 gene, rs4810485 and
which was in strong linkage disequilibrium with rs1883832
(r2 = 0.95), was reduced in arthritic patients when compared to
healthy controls. The broad functionality of CD40 on immune
responses, coupled with its critical role in several experimental
autoimmune conditions, such as collagen induced arthritis [8],
experimental Graves’ disease [9], experimental autoimmune
encephalomyelitis (EAE), a model of multiple sclerosis (MS) [10],
lupus nephritis [11] and type 1 diabetes [12] suggest its association
with other immune-mediated diseases. However, no association
has been detected with systemic lupus erythematosus [13] or with
type 1 diabetes [14] and, therefore, it would be interesting to
ascertain the diseases associated with the CD40 gene.
A recently performed genome-wide association study in MS
identified two genetically equivalent polymorphisms (r2 = 1) in the
59 region of the CD40 gene in strong linkage disequilibrium with
rs1883832C.T (r2 = 0.95) [15]. Interestingly, the susceptibility
allele described for Graves’ disease or rheumatoid arthritis seemed
to protect against MS, suggestive of a different molecular
mechanism involved in the aetiology of these conditions. Our
aim with the present study was to replicate this association with
MS and to confirm the protective effect of the common C allele at
position 21 of the CD40 gene.
Additionally, we pursued to test the effect of this polymorphism
in inflammatory bowel disease. Antibodies blocking CD40 have
been reported to dampen the severity of experimental colitis [16]
and a CD40 overexpression in Crohn’s disease lesions has been
known for a decade [17]. Thus, we decided to focus attention on
this component of the CD40/CD40-ligand costimulatory pathway
and to investigate the association of the functional polymorphism
of the CD40 gene in the two main clinical phenotypes of
inflammatory bowel disease, Crohn’s disease (CD) and ulcerative
colitis (UC).
Materials and Methods
Spanish patients (1564 MS, 1102 CD and 969 UC) and 2948
ethnically matched controls, mostly blood donors and staff, were
consecutively recruited from the following hospitals: H. Clı´nico S.
Carlos (Madrid), H. Virgen Macarena (Sevilla), H. Carlos Haya
and H. Virgen de la Victoria (Ma´laga), H. Clı´nico S. Cecilio and
H. Virgen de las Nieves (Granada), H. Puerta del Mar (Ca´diz) and
the Blood Bank (Granada). MS patients were diagnosed based on
the Poser criteria [18] and 37% of patients carried the HLA
DRB1*1501 allele. Most patients were relapsing remitting (79%),
19% secondary progressive and 2% primary progressive. Their
mean age at MS onset was 30610 years. Diagnosis of IBD patients
was based on standard clinical, radiologic, endoscopic and
histologic criteria [19]. Some UC patients suffered from pancolitis
(29%), extraintestinal manifestations (44%) or colectomy (27%).
CD patients were classified according to the location of the lesions
in ileal (L1, 40%), colonic (L2, 19%), ileocolonic (L3, 36%) and
upper gastrointestinal tract (L4, 4%) and according to the disease
behaviour in inflammatory (B1, 41%), stricturing (B2, 19%) and
perforating (B3, 40%). Subjects were included in the study after
informed consent. The Ethics Committee of the participant
hospitals approved the study.
Genotyping of the samples was carried out with a pre-designed
TaqMan Assay from Applied Biosystems in a 7900HT Fast Real-
Time PCR system, under the conditions recommended by the
manufacturer (Applied Biosystems, Foster City, CA, USA).
Genotyping call-rate success was over 96% for all patient groups
and controls.
The statistical analysis to compare allelic and genotypic
distributions was performed using chi-square test or Fisher’s exact
test included in a standard statistical package (Epi Info v. 5; World
Health Organization, Geneva, Switzerland) which was also used
for statistical power calculations. Odds ratios (OR) and their 95%
confidence intervals were estimated using the Cornfield method.
Linkage disequilibrium was measured by r2.
Results
Table 1 summarizes genotypic and allelic frequencies of the
functional CD40 polymorphism rs1883832 in Spanish patients
suffering from multiple sclerosis, Crohn’s disease or ulcerative
colitis and in ethnically-matched healthy controls. Results
conformed to Hardy-Weinberg expectations. As shown, the minor
allele frequency and the number of carriers of this minor allele
were higher in both MS and CD patients than in controls. This
increased susceptibility was not observed in UC patients. Being
this result in MS a replication of the original finding, there is no
need for correction. The significant result obtained in CD
withstands Bonferroni’s correction (x4).
No difference was observed in MS, CD and UC patients
stratified by the well-known susceptibility factors HLA-DRB1*
1501, NOD2/CARD15 or HLA-DRB1*103, respectively (data not
shown).
Table 1. Genotypic and allelic frequencies of the C/T21 polymorphism of the CD40 gene (p and OR values are shown for T allele
and carriers of T allele).
MS CD UC Controls MS vs. controls CD vs. controls UC vs. controls
rs1883832 n % n % n % n % p value OR (95% CI) p value OR (95% CI) p valueOR (95% CI)
TT 13 9 107 10 66 7 237 8
TC 7 41 452 42 398 42 1098 38 0.018 1.16 (1.0221.32) 0.002 1.24 (1.0821.43) 0.13 1.12 (0.9621.30)
CC 62 50 527 48 485 51 1562 54
T 89 29 666 31 530 27 1572 27 0.025 1.12 (1.0121.23) 0.002 1.19 (1.0621.33) 0.5 1.04 (0.9321.17)
C 9 71 1506 69 1368 73 4222 73
doi:10.1371/journal.pone.0011520.t001
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Discussion
The CD40/CD40-ligand pathway is a key component of the
pathophysiology of numerous autoimmune disorders [20]. Its
contribution to autoimmunity could involve different processes.
The physiological relevance of CD40/CD40-ligand in Th17-cell
differentiation has been recently proven using a mouse model of
experimental autoimmune encephalomyelitis and Cd402/2 mice
were found to be protected from the disease [21]. Increased
expression of the main cytokine produced by these T cells, IL-17,
has been shown in immune and inflammatory diseases including
rheumatoid arthritis, multiple sclerosis and inflammatory bowel
diseases [22–25]. Moreover, the functional blockade of CD40 with
a murine antibody effectively prevents clinical expression in an
animal model of multiple sclerosis [26]. Indeed, the preclinical
evaluation of a monoclonal antibody against CD40 has shown
beneficial activities in an MS model when administered early in
the disease development, as well as after the onset of brain
inflammation [27]. As mentioned, two of the three most associated
polymorphisms identified in a recent genome-wide association
study in MS [15] are proxies of the functional polymorphism at
21 of the CD40 gene. However, the minor allele of this variant
that decreases the efficiency of CD40 translation led to an
increased susceptibility towards the disease and we decided to
replicate this effect of the CD40 polymorphism in an independent
MS cohort. Our present data validate the original finding and
corroborate the association of the minor allele of this polymor-
phism in MS risk. Indeed, Buck et al. [28] observed a similar
increase in minor allele frequency in patients when compared to
controls (33% vs. 29%), although a limited statistical power
prevented them from reaching the significance threshold.
Then, we aimed at addressing the influence of the functional
polymorphism at 21 of the CD40 gene in inflammatory bowel
disease risk. Our data evidenced a parallel pattern of association of
CD and MS, with the minor allele conferring susceptibility to both
conditions. No significant effect of this polymorphism was detected
in the other main subphenotype of inflammatory bowel diseases,
UC, although the size of our collection would allow to detect the
effect previously described for the minor allele in MS risk
(OR = 1.18) with an 80% power (a= 0.05). A pattern of CD
susceptibility similar to the one herein described for the polymor-
phism at 21 in CD40 was evidenced in the genome-wide study
performed in CD by the Wellcome Trust Case Control Consortium
[29], where rs4810485 (proxy of rs1883832, r2 = 0.95) was
associated with CD [p=0.009; OR (95%CI)=1.14 (1.03–1.25)].
However, the significance threshold imposed in this type of whole-
genome scans hampered the consideration of this signal as a CD
susceptibility factor. Interestingly, in this WTCCC study, the minor
allele revealed a borderline significant signal of opposite effect in
rheumatoid arthritis [p=0.067; OR (95%CI)=0.91 (0.83–1.01)], in
agreement with the meta-analysis recently published (OR=0.87,
[7]). Therefore, the present data support the consideration of CD40
as a genuine risk factor for CD. Moreover, a significant difference
between the allelic frequencies of this polymorphism in CD and UC
patients is observed (p=0.027), concordantly with a recent study
showing that only half of the known genes associated with CD are
shared by UC [30].
As recently published by Zheng J et al. [31], CD8(+) Treg play
important roles in the maintenance of immune tolerance. Adoptive
transfer of these CD8(+) Treg in rodents or induction of CD8(+)
Treg in humans can prevent or treat autoimmune diseases. CD8(+)
T cell subsets could be induced from naive CD8(+) precursors in
vitro by allogenic CD40-activated B cells. Moreover, the Tregs
induced by CD40-B have greater suppressive capacity and are
generated in larger numbers than those induced by immature
dendritic cells [32]. Provided that the minor allele of the studied
CD40 variant decreases the efficiency of translation, this lower
amount of CD40 would then result in a reduced induction of Treg,
which would lead to a disruption of immune tolerance. Further
research regarding the balance of effector and regulatory T cells will
help to ascertain the pleiotropic action of CD40 signalling exerted
on several immune-mediated diseases, and provide clues for the
successful translation of new therapeutics.
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